Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder

George I. Papakostas, Timothy J. Petersen, Gustavo Kinrys, Alana M. Burns, John J. Worthington, Jonathan E. Alpert, Maurizio Fava, Andrew A. Nierenberg

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Background: Due to their favorable side effect profile, atypical antipsychotic agents offer important therapeutic advantages in mood disorders. Aripiprazole, an atypical antipsychotic agent with partial dopaminergic and serotonin 1A receptor agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI). Method: 12 patients (mean ± SD age = 46.6 ± 11.3 years, 66.7% female) with major depressive disorder (MDD) diagnosed by use of the Structured Clinical Interview for DSM-IV-Axis I Disorders, who had failed to experience a clinical response following an adequate trial of an SSRI, were treated with open-label aripiprazole in addition to their SSRI for 8 weeks. Clinical response was defined as a 50% or greater decrease in depressive symptoms during the course of the trial (baseline-endpoint) as measured by the 17-item Hamilton Rating Scale for Depression total score. Data were collected from August 2003 to July 2004. Results: 9/12 (75.0%) patients completed the trial. Using a completer analysis, 5/9 (55.6%) patients were classified as responders. An intent-to-treat (ITT) analysis resulted in 7 responders (58.3%). The overall proportion of remitters was 3/9 (33.3%) using a completer analysis and 5/12 (41.7%) using the ITT analysis. Aripiprazole administration appeared safe, with no severe adverse events observed in any of the study participants. Conclusions: These results suggest a possible augmentation role for aripiprazole when used in conjunction with SSRIs in SSRI-resistant MDD.

Original languageEnglish (US)
Pages (from-to)1326-1330
Number of pages5
JournalJournal of Clinical Psychiatry
Volume66
Issue number10
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Major Depressive Disorder
Serotonin Uptake Inhibitors
Antipsychotic Agents
Depression
Serotonin Receptor Agonists
Receptor, Serotonin, 5-HT1A
Mood Disorders
Diagnostic and Statistical Manual of Mental Disorders
Antidepressive Agents
Outpatients
Interviews
Aripiprazole

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Papakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., Alpert, J. E., ... Nierenberg, A. A. (2005). Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Journal of Clinical Psychiatry, 66(10), 1326-1330.

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. / Papakostas, George I.; Petersen, Timothy J.; Kinrys, Gustavo; Burns, Alana M.; Worthington, John J.; Alpert, Jonathan E.; Fava, Maurizio; Nierenberg, Andrew A.

In: Journal of Clinical Psychiatry, Vol. 66, No. 10, 10.2005, p. 1326-1330.

Research output: Contribution to journalArticle

Papakostas, GI, Petersen, TJ, Kinrys, G, Burns, AM, Worthington, JJ, Alpert, JE, Fava, M & Nierenberg, AA 2005, 'Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder', Journal of Clinical Psychiatry, vol. 66, no. 10, pp. 1326-1330.
Papakostas, George I. ; Petersen, Timothy J. ; Kinrys, Gustavo ; Burns, Alana M. ; Worthington, John J. ; Alpert, Jonathan E. ; Fava, Maurizio ; Nierenberg, Andrew A. / Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. In: Journal of Clinical Psychiatry. 2005 ; Vol. 66, No. 10. pp. 1326-1330.
@article{6c53812d9d5744589d0c6478d8d78b01,
title = "Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder",
abstract = "Background: Due to their favorable side effect profile, atypical antipsychotic agents offer important therapeutic advantages in mood disorders. Aripiprazole, an atypical antipsychotic agent with partial dopaminergic and serotonin 1A receptor agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI). Method: 12 patients (mean ± SD age = 46.6 ± 11.3 years, 66.7{\%} female) with major depressive disorder (MDD) diagnosed by use of the Structured Clinical Interview for DSM-IV-Axis I Disorders, who had failed to experience a clinical response following an adequate trial of an SSRI, were treated with open-label aripiprazole in addition to their SSRI for 8 weeks. Clinical response was defined as a 50{\%} or greater decrease in depressive symptoms during the course of the trial (baseline-endpoint) as measured by the 17-item Hamilton Rating Scale for Depression total score. Data were collected from August 2003 to July 2004. Results: 9/12 (75.0{\%}) patients completed the trial. Using a completer analysis, 5/9 (55.6{\%}) patients were classified as responders. An intent-to-treat (ITT) analysis resulted in 7 responders (58.3{\%}). The overall proportion of remitters was 3/9 (33.3{\%}) using a completer analysis and 5/12 (41.7{\%}) using the ITT analysis. Aripiprazole administration appeared safe, with no severe adverse events observed in any of the study participants. Conclusions: These results suggest a possible augmentation role for aripiprazole when used in conjunction with SSRIs in SSRI-resistant MDD.",
author = "Papakostas, {George I.} and Petersen, {Timothy J.} and Gustavo Kinrys and Burns, {Alana M.} and Worthington, {John J.} and Alpert, {Jonathan E.} and Maurizio Fava and Nierenberg, {Andrew A.}",
year = "2005",
month = "10",
language = "English (US)",
volume = "66",
pages = "1326--1330",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "10",

}

TY - JOUR

T1 - Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder

AU - Papakostas, George I.

AU - Petersen, Timothy J.

AU - Kinrys, Gustavo

AU - Burns, Alana M.

AU - Worthington, John J.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

AU - Nierenberg, Andrew A.

PY - 2005/10

Y1 - 2005/10

N2 - Background: Due to their favorable side effect profile, atypical antipsychotic agents offer important therapeutic advantages in mood disorders. Aripiprazole, an atypical antipsychotic agent with partial dopaminergic and serotonin 1A receptor agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI). Method: 12 patients (mean ± SD age = 46.6 ± 11.3 years, 66.7% female) with major depressive disorder (MDD) diagnosed by use of the Structured Clinical Interview for DSM-IV-Axis I Disorders, who had failed to experience a clinical response following an adequate trial of an SSRI, were treated with open-label aripiprazole in addition to their SSRI for 8 weeks. Clinical response was defined as a 50% or greater decrease in depressive symptoms during the course of the trial (baseline-endpoint) as measured by the 17-item Hamilton Rating Scale for Depression total score. Data were collected from August 2003 to July 2004. Results: 9/12 (75.0%) patients completed the trial. Using a completer analysis, 5/9 (55.6%) patients were classified as responders. An intent-to-treat (ITT) analysis resulted in 7 responders (58.3%). The overall proportion of remitters was 3/9 (33.3%) using a completer analysis and 5/12 (41.7%) using the ITT analysis. Aripiprazole administration appeared safe, with no severe adverse events observed in any of the study participants. Conclusions: These results suggest a possible augmentation role for aripiprazole when used in conjunction with SSRIs in SSRI-resistant MDD.

AB - Background: Due to their favorable side effect profile, atypical antipsychotic agents offer important therapeutic advantages in mood disorders. Aripiprazole, an atypical antipsychotic agent with partial dopaminergic and serotonin 1A receptor agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. The purpose of this study was to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI). Method: 12 patients (mean ± SD age = 46.6 ± 11.3 years, 66.7% female) with major depressive disorder (MDD) diagnosed by use of the Structured Clinical Interview for DSM-IV-Axis I Disorders, who had failed to experience a clinical response following an adequate trial of an SSRI, were treated with open-label aripiprazole in addition to their SSRI for 8 weeks. Clinical response was defined as a 50% or greater decrease in depressive symptoms during the course of the trial (baseline-endpoint) as measured by the 17-item Hamilton Rating Scale for Depression total score. Data were collected from August 2003 to July 2004. Results: 9/12 (75.0%) patients completed the trial. Using a completer analysis, 5/9 (55.6%) patients were classified as responders. An intent-to-treat (ITT) analysis resulted in 7 responders (58.3%). The overall proportion of remitters was 3/9 (33.3%) using a completer analysis and 5/12 (41.7%) using the ITT analysis. Aripiprazole administration appeared safe, with no severe adverse events observed in any of the study participants. Conclusions: These results suggest a possible augmentation role for aripiprazole when used in conjunction with SSRIs in SSRI-resistant MDD.

UR - http://www.scopus.com/inward/record.url?scp=27544477735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544477735&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 1326

EP - 1330

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 10

ER -